Next week, NCI will announce its plans for surviving on an austere budget given to it by Congress as fiscal year 2024 approaches the six-month mark.
Soon after he was diagnosed with a dedifferentiated liposarcoma, C. Norman Coleman reached out to The Cancer Letter and the Cancer History Project to initiate a series of interviews about his life and career.
When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
Sometimes in oncology, you get “beat-the-reaper” stories.
As a new deputy director at UPMC Hillman Cancer Center, Monica Baskin has assumed a level of responsibility that is unusual, if not unprecedented, for a population scientist at an NCI-designated cancer center.
Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
A month after reporting to work in the top job at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Taofeek K. Owonikoko reflected on the obligations that come with being a Black director of an NCI-designated cancer center.
Shikha Jain, Shea Holman: It’s time for NIH to be transparent about how misconduct cases are handled
NIH has until Feb. 20 to comply with a congressional subpoena that directs NIH Director Monica Bertagnolli to produce internal documents, including reports and whistleblower complaints that could shed light on whether NIH is adequately responding to complaints of workplace misconduct and sexual harassment.
As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.
When Naoto T. Ueno left MD Anderson to become director of the University of Hawaiʻi Cancer Center, he took one of the most challenging jobs in oncology.
